BIO at a glance
Bio-rad Laboratories Inc (BIO, SEC CIK 12208) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as September 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Bio-rad Laboratories Inc (BIO) reported revenue of $2.6 billion (up 0.7% from FY2024) and net income of $759.9 million. Diluted EPS was $27.85.
- As of June 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Bio-rad Laboratories Inc (BIO) shares worth $2.1 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.6B
- +0.7% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 36 funds
- $2.1B · −1 vs prior quarter
- Latest 10-Q
- Aug 4, 2026
- Quarterly report
SignalX for BIO
Don't miss the next BIO filing
- Alerts as it files. A push when BIO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BIO, by share count.
- Ask anything. An AI agent that reads every BIO filing and answers with sources.
BIO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| BARRY JAMES | M | Sep 6, 2026 | 1,056 | - |
| ENLOE COURTNEY C | M | Sep 6, 2026 | 768 | - |
| ENGELHARDT EVA ANETTE | M | Sep 6, 2026 | 1,152 | - |
| BARRY JAMES | F | Sep 6, 2026 | 470 | $386.11 |
| ENLOE COURTNEY C | M | Sep 6, 2026 | 768 | - |
| ENLOE COURTNEY C | F | Sep 6, 2026 | 305 | $386.11 |
| ENGELHARDT EVA ANETTE | M | Sep 6, 2026 | 1,152 | - |
| ENGELHARDT EVA ANETTE | F | Sep 6, 2026 | 485 | $386.11 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.6B | $2.6B |
| Gross Profit | - | $1.4B | $1.3B |
| Operating Income | - | $269.0M | $47.2M |
| Net Income | - | -$1.8B | $759.9M |
| Gross Margin | - | 53.7% | 51.9% |
| Op. Margin | - | 10.5% | 1.8% |
| Net Margin | - | -71.9% | 29.4% |
| Balance Sheet | |||
| Total Assets | $12.3B | $9.4B | $10.6B |
| Equity | $8.7B | $6.6B | $7.5B |
| ROE | - | -28.1% | 10.2% |
| Per Share | |||
| EPS | - | $-65.36 | $27.85 |
| Cash Flow | |||
| Operating CF | - | $455.2M | $532.2M |
| CapEx | - | $165.6M | $157.6M |
Source: XBRL data in Bio-rad Laboratories Inc (BIO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BIO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 36 | $2.09B |
| Q1 2026 | 37 | $1.96B |
| Q4 2025 | 33 | $2.01B |
| Q3 2025 | 34 | $1.94B |
| Q2 2025 | 31 | $1.71B |
| Q1 2025 | 28 | $1.33B |
| Q4 2024 | 27 | $1.56B |
| Q3 2024 | 24 | $941.4M |
- Goldman Sachs Group+128.2K (+242%)
- AQR Capital Management+98.2K (+104%)
- Wells Fargo & Co+76.8K (+372%)
- Millennium Management+56.6K (+1718%)
- Bank of America Corp+45.5K (+10%)
- Dimensional Fund Advisors−144.8K (-13%)
- Citadel Advisors LLC−87.8K (-59%)
- Morgan Stanley−83.6K (-31%)
- T. Rowe Price Group−55.0K (-74%)
- BNY Mellon−13.0K (-10%)
- Allstate+3.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 250 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BIO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
- ILMN · Illumina IncLaboratory Analytical Instruments
BIO SEC filings: frequently asked questions
Which institutions hold BIO stock?
As of June 30, 2026, the largest Bio-rad Laboratories Inc (BIO) holders among the 13F filers tracked by SignalX were BlackRock ($498.8 million), Dimensional Fund Advisors ($277.3 million), Vanguard Capital Management LLC ($242.8 million), Vanguard Portfolio Management LLC ($239.6 million), State Street Corp ($167.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BIO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Bio-rad Laboratories Inc (BIO) reported revenue of $2.6 billion (up 0.7% from FY2024) and net income of $759.9 million. Diluted EPS was $27.85. The figures come from the XBRL data in the 10-K.
What are the latest BIO SEC filings?
Bio-rad Laboratories Inc (BIO) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on September 9, 2026.
What is BIO's SEC CIK number?
Bio-rad Laboratories Inc (BIO)'s SEC Central Index Key (CIK) is 12208. EDGAR lists every BIO filing under that number.
Ask anything about BIO
The research agent reads BIO's filings, financials, insider trades and 13F holders, then answers with sources.